| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Astellas) 7465-CL-0301 | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Hotte, Dr Sebastien | Open to recruitment | NCT03474107 |
| (AstraZeneca) D933IC00003 / BAYOU | A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03459846 |
| (Bayer) BAY 1163877 / 17403 / FORT-1 | A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum containing chemotherapy | Hotte, Dr Sebastien | Open to recruitment | NCT03410693 |
| (BMS) CA018005 / FRACTION-RCC | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma | Hotte, Dr Sebastien | Open to recruitment | NCT02996110 |
| (BMS) CA2099KD / CheckMate 9KD | A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD) | Hotte, Dr Sebastien | Open to recruitment | NCT03338790 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (Master) |
| (CCTG) IND.234 / PC-BETS - Sub-Study IND.223 | A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT02905318 |
| (CCTG) IND.234A/PC-BETS Sub-Study A | A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (A) |
| (CCTG) IND.234B/PC-BETS Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(B) |
| (CCTG) IND.234C/PC-BETS Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(C) |
| (Clovis) CO-338-052 / TRITON2 | A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Hotte, Dr Sebastien | Open to recruitment | NCT02952534 |
| (EISAI) E7080-G000-218 / HOPE | A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment | Hotte, Dr Sebastien | Open to recruitment | NCT03173560 |
| (JCC) Prostate HBI | Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer | Dayes, Dr Ian | Open to recruitment | NCT03196778 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Open to recruitment | NCT02685397 |
| (Merck) MK-3475-564 / KEYNOTE 564 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03142334 |
| (PHRI) RADICAL PC2 | A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients | Leong, Dr Darryl | Open to recruitment | NCT03127631 |
| (Roche) CO39303 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Mukherjee, Dr Som | Open to recruitment | NCT03072238 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Open to recruitment | NCT02462239 |
| OCOG-2016-MISTER | Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer | Hotte, Dr Sebastien | Open to recruitment | NCT02813226 |
| (UHN) TOPCOP | TOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study) | Hotte, Dr Sebastien | Suspended/On hold | NCT02512185 |
Find a Trial
Contact Us